# Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

> **NCT01525199** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 450 (estimated)

## Conditions studied

- Stage IIIB/IV
- Non-Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01525199
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2014-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01525199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01525199, "Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.". Retrieved via AI Analytics 2026-06-20 from https://api.ai-analytics.org/clinical/NCT01525199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*